Respiratory Tract Diseases: Clinical Trials

52,269 trials for Respiratory Tract Diseases, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

28743 completed, 8641 unknown, 4993 recruiting, 3762 terminated. 14856 Not applicable, 10170 Phase 2, 5893 Phase 1, 5755 Phase 3, 3036 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable14856Completed 8177, Unknown 2595, Recruiting 1489, Terminated 783, Not yet recruiting 760, Withdrawn 472, Active not recruiting 414, Enrolling by invitation 116, Suspended 50
Phase 210170Completed 5116, Unknown 1347, Terminated 1286, Recruiting 1009, Withdrawn 521, Active not recruiting 472, Not yet recruiting 363, Suspended 36, Enrolling by invitation 20
Phase 15893Completed 3278, Terminated 723, Recruiting 631, Unknown 531, Active not recruiting 295, Withdrawn 256, Not yet recruiting 143, Suspended 28, Enrolling by invitation 8
Phase 35755Completed 3456, Unknown 694, Terminated 580, Recruiting 405, Withdrawn 238, Active not recruiting 223, Not yet recruiting 126, Suspended 21, Enrolling by invitation 12
Phase 43036Completed 1884, Unknown 460, Terminated 251, Recruiting 168, Withdrawn 115, Not yet recruiting 79, Active not recruiting 64, Suspended 9, Enrolling by invitation 6
Early Phase 1427Completed 177, Unknown 90, Recruiting 51, Terminated 40, Withdrawn 24, Not yet recruiting 22, Active not recruiting 14, Enrolling by invitation 5, Suspended 4

Follow Respiratory Tract Diseases: new trials by email Literature Review of Respiratory Tract Diseases trials Research Report on Respiratory Tract Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
PAP Systems External Clinical Studies (ECS)
PAP System A (with Amalfi) then PAP System B (with CLA11), PAP System B (with CLA11) then PAP System A (with Amalfi) - Obstructive Sleep Apnea
Not applicableNot yet recruitingResMed302028-08-012026-04-24
Acoustic Resonance Therapy for Treating Empty Nose Syndrome
Personalized ART, Non-personalized ART - Empty Nose Syndrome, Nasal Obstruction
Not applicableNot yet recruitingStanford University402028-07-012025-10-10
EFFECT OF AYURVEDA TREATMENT IN ALLERGIC RHINITIS
AYURVEDA treatment protocol, Control(Citrizine 10mg) - Allergic Rhinitis (AR)
Not applicableNot yet recruitingAmrita Vishwa Vidyapeetham1042028-06-302026-06-04
Bubble CPAP Team-Based Care Strategy Feasibility Trial
bCPAP team-based care strategy - Pneumonia in Children
Not applicableNot yet recruitingYale University952028-04-012026-06-02
Adiposity Distribution in Acute Respiratory Failure
PEEP Titration Using Electrical Impedance Tomography (EIT), Body Positioning: Supine and Prone - Acute Hypoxemic Respiratory Failure, Obesity
Not applicableNot yet recruitingMaurizio F. Cereda, MD802028-01-012025-06-13
PulmoSalud: Multimodal Program for Prehabilitation and Early Home Rehabilitation in Patients With Lung Cancer
Individualized pre-operative physical exercise, Post-operative rehabilitation physical exercise, Respiratory physiotherapy Prehabilitation - Lung Cancer
Not applicableNot yet recruitingFranciscoVeraSerrano842028-01-012026-03-17
Chronic COUGH Management in Interstitial Lung DisEase
Non-pharmacological cough control therapy, Healthy lifestyle - Interstitial Lung Disease, Chronic Cough
Not applicableNot yet recruitingAveiro University602027-12-202025-01-20
Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 6 of 7)
Visible light exposure - Exposure to Man-made Visible Light
Not applicableNot yet recruitingUniversity of Bern502027-12-012026-01-14
A Personalized Voice Restoration Device for Patients With Laryngectomy
Surface Electromyography - Dysphonia, Aphonia
Not applicableNot yet recruitingWeill Medical College of Cornell University1002027-12-012026-06-16
Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7)
Visible light exposure - Exposure to Man-made Visible Light
Not applicableNot yet recruitingUniversity of Bern502027-12-012026-01-14
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingRemeGen Co., Ltd.262027-12-012026-09-22
Symptom Management to Improve Completion of Patient-reported Outcome Measures
Monitoring of PROMIS symptoms and physical function, Monitoring of additional symptoms and symptom self-management - Malignant Solid Neoplasm, Malignant Head and Neck Neoplasm
Not applicableNot yet recruitingHenry Ford Health System782027-10-012026-07-29
Developing an Intervention to Optimize Virtual Care Adoption for COPD Management
VC-OPTIONS - Chronic Obstructive Pulmonary Disease
Not applicableNot yet recruitingVA Office of Research and Development402027-09-022026-09-29
A Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of MN-08 Tablets
MN-08 24 mg/day, MN-08 60 mg/day - Pulmonary Arterial Hypertension
Phase 1Not yet recruitingGuangzhou Magpie Pharmaceuticals Co., Ltd.162027-09-012026-09-14
Remote Intervention Versus Routine Monitoring in COPD Patients With Chronic Hypercapnia Receiving Home Non-invasive Respiratory Support
Remote Management, Remote Monitoring Only - COPD (Chronic Obstructive Pulmonary Disease), Acute Exacerbation of COPD
Not applicableNot yet recruitingSir Run Run Shaw Hospital2362027-08-012026-08-06
Perceptions of Undergraduate Students and Teaching Staff on Online Teaching
Questionnaire - Covid19
SuspendedMisr International University92092027-07-152026-10-08
Optimizing Dysphagia Treatment Delivery in Acute Care: A Hybrid Efficacy Implementation Trial
Expiratory muscle strength training (EMST), Standard of Care Dysphagia Treatment, Intensive Dysphagia Treatment - Dysphagia, Critical Illness
Not applicableNot yet recruitingVanderbilt University Medical Center1202027-07-012026-10-14
RSV Vaccination to Reduce Recurrent AECOPD
RSV vaccination (Arexvy, GlaxoSmithKline) - COPD, RSV
Phase 4Not yet recruitingChinese University of Hong Kong3202027-07-012026-04-13
cfMSC Stem Cell Therapy Targeting COPD
clonal fetal MSCs - Chronic Obstructive Pulmonary Disease (COPD)
Phase 1 / Phase 2Not yet recruitingShenzhen Geno-Immune Medical Institute302027-06-302026-08-27
A Master Trial Assessing the Technical Feasibility of First-In-Human Real-Time Image Guided Radiation Therapy Methods
Real-Time Image Guided Radio Therapy (IGRT) - Cancer
Not applicableNot yet recruitingUniversity of Sydney402027-06-012026-05-20

Showing 20 of 52269. Sign in to see all of them.

Narrower conditions

COVID-19 (7570)  ·  Carcinoma, Non-Small-Cell Lung (7064)  ·  Pulmonary Disease, Chronic Obstructive (5327)  ·  Lung Neoplasms (5255)  ·  Asthma (4458)  ·  Influenza, Human (2157)  ·  Sleep Apnea, Obstructive (2155)  ·  Cystic Fibrosis (1578)  ·  Pneumonia (1383)  ·  Respiratory Insufficiency (1343)  ·  Respiratory Distress Syndrome (1340)  ·  Small Cell Lung Carcinoma (1198)  ·  Lung Diseases (1153)  ·  Neoplasms (1082)  ·  Sleep Apnea Syndromes (1078)

Broader conditions

Lung Diseases (38801)  ·  Pathological Conditions, Signs and Symptoms (15118)  ·  Infections (15092)  ·  Respiratory Tract Infections (13943)  ·  Neoplasms by Site (12252)  ·  Respiratory Tract Neoplasms (11912)  ·  Neoplasms (11760)  ·  Thoracic Neoplasms (11663)  ·  Pathologic Processes (11466)  ·  Virus Diseases (10583)  ·  RNA Virus Infections (10575)  ·  Lung Diseases, Obstructive (10358)  ·  Pneumonia (8697)  ·  Respiration Disorders (8562)

Interventions

Carboplatin (1086)  ·  Cisplatin (853)  ·  Pemetrexed (746)  ·  pembrolizumab (599)  ·  Paclitaxel (582)  ·  Docetaxel (515)  ·  Blood Specimen Collection (442)  ·  Influenza Vaccines (440)  ·  Standard of Care (429)  ·  Radiotherapy (412)  ·  Gemcitabine (400)  ·  Sodium Chloride (348)  ·  Continuous Positive Airway Pressure (346)  ·  Erlotinib Hydrochloride (337)  ·  Nivolumab (328)

Sponsors

GlaxoSmithKline (1013)  ·  AstraZeneca (867)  ·  Assistance Publique - Hôpitaux de Paris (492)  ·  Boehringer Ingelheim (476)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (394)  ·  Pfizer (380)  ·  National Cancer Institute (NCI) (359)  ·  Novartis Pharmaceuticals (353)  ·  Assiut University (351)  ·  M.D. Anderson Cancer Center (263)  ·  Mayo Clinic (235)  ·  National Heart, Lung, and Blood Institute (NHLBI) (211)  ·  Merck Sharp & Dohme LLC (209)  ·  National Taiwan University Hospital (206)  ·  Massachusetts General Hospital (196)

Countries

United States (16675)  ·  China (5236)  ·  France (4780)  ·  United Kingdom (3608)  ·  Canada (3566)  ·  Germany (3206)  ·  Spain (2966)  ·  Italy (2774)  ·  Turkey (Türkiye) (1986)  ·  Belgium (1859)  ·  South Korea (1730)  ·  Netherlands (1697)  ·  Australia (1622)  ·  Poland (1499)  ·  Brazil (1470)

Results publications

PMID 34473343, PMID 36472162, PMID 37983082, PMID 33331662, PMID 35244208, PMID 33511633, PMID 35713300, PMID 31986264, PMID 32031570, PMID 32091533, PMID 32109013, PMID 32171076, PMID 33502773, PMID 34013969, PMID 36734509, PMID 37162745, PMID 27881132, PMID 36695483, PMID 37010196, PMID 37489818, PMID 37591523, PMID 26903337, PMID 34495549, PMID 34658014, PMID 35688625, PMID 32167524, PMID 32943047, PMID 10793162, PMID 12091180, PMID 23688302, PMID 33710614, PMID 35815359, PMID 39393433, PMID 42149813, PMID 32250385, PMID 34350582, PMID 37542951, PMID 22797452, PMID 25693014, PMID 31319851, PMID 31401903, PMID 32142651, PMID 32192578, PMID 17507545, PMID 25981908, PMID 29400693, PMID 32007143, PMID 32105632, PMID 32926419, PMID 33044747

NIH funding

2023 (295), 2018 (187), 2015 (179), 2017 (173), 2016 (165), 2019 (162), 2025 (147), 2014 (131), 2009 (129), 2008 (87), U10CA031946 (52), P30CA033572 (38), U10CA032102 (37), 2005 (29), P30CA012197 (28)